Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
$37.75−1.03 (-2.66%)
Close on Nov 18, 2026Market cap $3.66BP/E –Yield –
Xenon Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Xenon Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $7.50M. Over ten years it grew -12.5% a year on average. The highest annual figure on record is $32.17M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.50M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $9.43M | -48.8% |
| FY2021 | Dec 31, 2021 | $18.44M | -42.7% |
| FY2020 | Dec 31, 2020 | $32.17M | +371.0% |
| FY2019 | Dec 31, 2019 | $6.83M | +2095.8% |
| FY2017 | Dec 31, 2017 | $311.00K | -82.8% |
| FY2016 | Dec 31, 2016 | $1.80M | -88.4% |
| FY2015 | Dec 31, 2015 | $15.58M | -45.1% |
| FY2014 | Dec 31, 2014 | $28.37M | +3.7% |
| FY2013 | Dec 31, 2013 | $27.36M | +91.2% |
| FY2012 | Dec 31, 2012 | $14.31M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $7.50M | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $132.00K | -98.4% |
| Q2 FY2022 | Jun 30, 2022 | $536.00K | -75.8% |
| Q1 FY2022 | Mar 31, 2022 | $8.77M | +101.1% |
| Q4 FY2021 | Dec 31, 2021 | $3.74M | -27.4% |
| Q3 FY2021 | Sep 30, 2021 | $8.12M | +24.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.22M | -83.4% |
| Q1 FY2021 | Mar 31, 2021 | $4.36M | -38.4% |
| Q4 FY2020 | Dec 31, 2020 | $5.15M | +54.7% |
| Q3 FY2020 | Sep 30, 2020 | $6.55M | +87.3% |
| Q2 FY2020 | Jun 30, 2020 | $13.38M | +83550.0% |
| Q1 FY2020 | Mar 31, 2020 | $7.08M | +2581.1% |
| Q4 FY2019 | Dec 31, 2019 | $3.33M | +22093.3% |
| Q3 FY2019 | Sep 30, 2019 | $3.50M | +21775.0% |
| Q4 FY2017 | Dec 31, 2017 | $16.00K | -95.7% |
| Q3 FY2017 | Sep 30, 2017 | $264.00K | -36.1% |
| Q2 FY2017 | Jun 30, 2017 | $15.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $16.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $376.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $413.00K | – |
See a number that looks wrong?